The Israeli molecular diagnostics company will use artificial intelligence and phenotypic analysis to increase the diagnostic rate of its genetic tests.
The Vanderbilt Center for Undiagnosed Diseases will use FDNA's Face2Gene to help evaluate difficult-to-diagnose patients.
PreventionGenetics will use FDNA's technology to expand the diagnostic ability of its testing and interpretation services.
FDNA's technology uses facial analysis, deep learning, and AI to evaluate symptoms of patients with rare genetic diseases and suggest possible diagnoses.
The partnership combines sequencing with phenotype information to help diagnose patients with rare diseases.
MCRI is planning to integrate its POSSUMweb database into FDNA's Face2Gene software, in order to enhance its library of genetic syndrome data and images.
The deal will join the AmbryPort 2.0 clinical ordering platform with FDNA's Face2Gene next-generation phenotyping application suite.
FDNA's technology uses facial analysis, deep learning, and artificial intelligence to evaluate symptoms of patients with rare genetic diseases.
The integration could provide a more complete phenotypic picture that helps clinicians prioritize genetic variants that may have otherwise been missed.
The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.
A small study finds differences between three genomic prostate cancer tests, Medscape reports.
In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.
A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.